Large-scale plasma lipidomic profiling identifies lipids that predict cardiovascular events in secondary prevention

PA Mundra; CK Barlow; PJ Nestel; EH Barnes; A Kirby; P Thompson; DR Sullivan; ZH Alshehry; NA Mellett; K Huynh; KS Jayawardana; C Giles; MJ McConville; S Zoungas; GS Hillis; J Chalmers; M Woodward; G Wong; BA Kingwell; J Simes; AM Tonkin; PJ Meikle

Journal article

Large-scale plasma lipidomic profiling identifies lipids that predict cardiovascular events in secondary prevention

PA Mundra, CK Barlow, PJ Nestel, EH Barnes, A Kirby, P Thompson, DR Sullivan, ZH Alshehry, NA Mellett, K Huynh, KS Jayawardana, C Giles, MJ McConville, S Zoungas, GS Hillis, J Chalmers, M Woodward, G Wong, BA Kingwell, J Simes Show all

Jci Insight | AMER SOC CLINICAL INVESTIGATION INC | Published : 2018

DOI: 10.1172/jci.insight.121326

Abstract

BACKGROUND: Plasma lipidomic measures may enable improved prediction of cardiovascular outcomes in secondary prevention. The aim of this study is to determine the association of plasma lipidomic measurements with cardiovascular events and assess their potential to predict such events. METHODS: Plasma lipids (n = 342) were measured in a retrospective subcohort (n = 5,991) of the LIPID study. Proportional hazards regression was used to identify lipids associated with future cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and cardiovascular death. Multivariable models adding lipid species to traditional risk factors were created using lipid ranki..

View full abstract

University of Melbourne Researchers

Kaushala Jayawardana Author

Corey Giles Author

Malcolm McConville Author

Bronwyn Kingwell Author

Grants

Awarded by National Health and Medical Research Council of Australia

Funding Acknowledgements

We would like to thank the investigators of the LIPID and ADVANCE studies and the patients who participated in these studies. We acknowledge Michelle Cinel and Ricardo Tan for their technical support in the lipidomic analyses. The LIPID study was supported by a research grant from Bristol-Myers Squibb and was conducted independently of the sponsor, under the auspices of the National Heart Foundation of Australia. The ADVANCE study was funded by the National Health and Medical Research Council of Australia (grants 211086 and 358395). This work was funded by the National Health and Medical Research Council of Australia (grant 1029754) and the Operational Infrastructure Support Program of the Victorian Government of Australia. See the Supplemental Acknowledgments for The LIPID study Investigators details.